Clinical Trials

NCT IdNCT04872543
TitleA Study of ASTX727 in People With Malignant Peripheral Nerve Sheath Tumors (MPNST)
ConditionMalignant Peripheral Nerve Sheath Tumors (MPNST)
StudyTypeInterventional
OrganizationMemorial Sloan Kettering Cancer Center
Sponsor/CollaboratorsMemorial Sloan Kettering Cancer Center
StatusRecruiting
GenderAll
AgeGroupAdult
Older Adult
Location (with distance)
  • Memorial Sloan Kettering Cancer Center, New York, 10065 , United States
DescriptionThe purpose of this study is to see whether the study drug ASTX727 is an effective treatment for people who have MPNST with a PCR2 mutation. ASTX727 is a combination of two drugs (cedazuridine and decitabine) that have been designed to target cancer cells with a PCR2 mutation and to disrupt the cells' ability to survive and grow. The study researchers think that the study drug allows decitabine to work better than decitabine given alone.